Battle for Market Share: Major Health News Briefs

This content covers various health news briefs, including the competition among pharmaceutical companies for RSV vaccine market share, settlement of a Zantac lawsuit, a pay rise deal for UK junior doctors, Revvity's profit forecast increase, Greece's efforts to contain 'goat plague,' Roche's weight-loss drug plans, and FDA approval of Guardant Health's cancer test.

Fierce competition among Pfizer, GSK, and Moderna for RSV vaccine market share is under Wall Street's watch, as companies reveal negotiation strategies with pharmacies. Meanwhile, GSK has settled a Zantac-related cancer lawsuit in Illinois confidentially, continuing to manage costly litigation over the discontinued heartburn drug.

In the UK, junior doctors have secured an average pay increase of 22.3% over two years, potentially ending disruptive strikes. Medical equipment maker Revvity has raised its profit forecast owing to strong diagnostic product demand.

Greece has banned the movement of sheep and goats to contain 'goat plague.' Roche aims to fast-track the development of its anti-obesity drugs to rival existing market leaders. Guardant Health's blood-based cancer test has gained U.S. FDA approval, boosting company shares. Additionally, Philips reported higher-than-expected profits due to cost savings.

Sinergium Biotech will share bird flu vaccine data with low and middle-income countries for equitable pandemic response. Lastly, Abbott Laboratories' shares fell sharply after a jury ordered the company to pay damages over a premature infant formula, affecting rival Reckitt Benckiser.

(With inputs from agencies.)